ESR1 and breast carcinoma: Notably, the prognostic T-lymphocyte marker CD8A was able to stratify the major group of estrogen receptor positive (ER+) breast cancer patients into groups with high and low survival risk independently of using RNA or iRNA expression and a similar trend was seen when analyzing all breast cancer samples (Fig. 3e and Additional file 7: Fig. S3c).